Should you buy Catalyst Pharmaceuticals (cat) stock?

Yet another reason to like Catalyst Pharmaceuticals stock is its current valuation. Its price-to-earnings (P/E) multiple of 24.8 is pretty much exactly in the middle of the pack when compared to its industry or to the wider market. While it's no bargain, its valuation is unlikely to go lower if its top and bottom lines are thriving.

Where is Catalyst Pharmaceuticals Inc headquartered?

The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL. CPRX | Complete Catalyst Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

What are Catalyst Pharmaceuticals' share price targets?

5 brokers have issued 1 year price targets for Catalyst Pharmaceuticals' shares. Their CPRX share price targets range from $23.00 to $34.00. On average, they expect the company's share price to reach $26.71 in the next twelve months. This suggests a possible upside of 57.9% from the stock's current price.